IL145586A0 - Antisense oligonucleotides comprising universal and/or degenerate bases - Google Patents

Antisense oligonucleotides comprising universal and/or degenerate bases

Info

Publication number
IL145586A0
IL145586A0 IL14558600A IL14558600A IL145586A0 IL 145586 A0 IL145586 A0 IL 145586A0 IL 14558600 A IL14558600 A IL 14558600A IL 14558600 A IL14558600 A IL 14558600A IL 145586 A0 IL145586 A0 IL 145586A0
Authority
IL
Israel
Prior art keywords
universal
antisense oligonucleotides
degenerate bases
degenerate
bases
Prior art date
Application number
IL14558600A
Other languages
English (en)
Original Assignee
Oasis Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oasis Biosciences Inc filed Critical Oasis Biosciences Inc
Publication of IL145586A0 publication Critical patent/IL145586A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14558600A 1999-04-08 2000-04-07 Antisense oligonucleotides comprising universal and/or degenerate bases IL145586A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12837799P 1999-04-08 1999-04-08
PCT/US2000/009293 WO2000061810A1 (en) 1999-04-08 2000-04-07 Antisense oligonucleotides comprising universal and/or degenerate bases

Publications (1)

Publication Number Publication Date
IL145586A0 true IL145586A0 (en) 2002-06-30

Family

ID=22435071

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14558600A IL145586A0 (en) 1999-04-08 2000-04-07 Antisense oligonucleotides comprising universal and/or degenerate bases

Country Status (8)

Country Link
US (1) US20030045488A1 (xx)
EP (1) EP1173614A4 (xx)
JP (1) JP2002541825A (xx)
KR (1) KR20020013519A (xx)
AU (1) AU777499B2 (xx)
CA (1) CA2365984A1 (xx)
IL (1) IL145586A0 (xx)
WO (1) WO2000061810A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
WO2001085996A1 (en) 2000-05-09 2001-11-15 Isis Pharmaceuticals, Inc. Methods of obtaining active antisense compounds
US9261460B2 (en) * 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
US9771578B2 (en) * 2002-11-05 2017-09-26 Ionis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
US7256284B2 (en) 2002-11-14 2007-08-14 Genta Incorporated Inhibitory oligonucleotides targeted to Bcl-2
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
ES2351976T3 (es) 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
EP1667731B1 (en) * 2003-10-01 2013-05-22 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2008271050B2 (en) * 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
ES2914775T3 (es) 2007-10-26 2022-06-16 Academisch Ziekenhuis Leiden Medios y métodos para contrarresta trastornos del músculo
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA2759899A1 (en) * 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9506057B2 (en) 2010-03-26 2016-11-29 Integrated Dna Technologies, Inc. Modifications for antisense compounds
CA2809457C (en) * 2010-09-07 2019-07-30 Integrated Dna Technologies, Inc. Modifications for antisense compounds
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
KR101742681B1 (ko) * 2015-01-30 2017-06-01 에스디 바이오센서 주식회사 상보적 염기서열 내지는 미스-매치된 염기를 포함하는 상보적인 염기서열과 연결된 pcr 프라이머 및 이를 이용한 핵산 증폭 방법
WO2016196670A1 (en) 2015-06-01 2016-12-08 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
JP7394753B2 (ja) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド アンチセンスオリゴマー化合物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US5112974A (en) * 1985-01-18 1992-05-12 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents to DNA
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6984487B1 (en) * 1989-08-22 2006-01-10 Hsc Research Development Corporation Cystic fibrosis gene
US5104792A (en) * 1989-12-21 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Method for amplifying unknown nucleic acid sequences
US5623065A (en) * 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5541307A (en) * 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
EP0502180B1 (en) * 1990-09-21 1997-04-16 Amgen Inc. Enzymatic synthesis of oligonucleotides
US5500357A (en) * 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
US5627032A (en) * 1990-12-24 1997-05-06 Ulanovsky; Levy Composite primers for nucleic acids
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1993005182A1 (en) * 1991-09-05 1993-03-18 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
US5612199A (en) * 1991-10-11 1997-03-18 Behringwerke Ag Method for producing a polynucleotide for use in single primer amplification
US5981179A (en) * 1991-11-14 1999-11-09 Digene Diagnostics, Inc. Continuous amplification reaction
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5424413A (en) * 1992-01-22 1995-06-13 Gen-Probe Incorporated Branched nucleic acid probes
JP3530186B2 (ja) * 1992-03-05 2004-05-24 アイシス・ファーマシューティカルス・インコーポレーテッド 共有架橋オリゴヌクレオチド
GB9210273D0 (en) * 1992-05-13 1992-07-01 Ici Plc Dna
US6346614B1 (en) * 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
DE69310179T2 (de) * 1992-07-31 1997-07-31 Behringwerke Ag Verfahren zur einführung von definierten sequenzen am 3' ende von polynukleotiden
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5438131A (en) * 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
US5583032A (en) * 1992-10-21 1996-12-10 The Cleveland Clinic Foundation And National Institutes Of Health Method of cleaving specific strands of RNA
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds
US5571902A (en) * 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US6150141A (en) * 1993-09-10 2000-11-21 Trustees Of Boston University Intron-mediated recombinant techniques and reagents
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
JP3418043B2 (ja) * 1995-02-15 2003-06-16 富士写真フイルム株式会社 発色現像主薬、ハロゲン化銀写真感光材料および画像形成方法
US5801155A (en) * 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
US6372427B1 (en) * 1995-04-12 2002-04-16 Hybridon, Inc. Cooperative oligonucleotides
US5668748A (en) * 1995-04-15 1997-09-16 United Microelectronics Corporation Apparatus for two-dimensional discrete cosine transform
US5843650A (en) * 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
US5728818A (en) * 1996-01-16 1998-03-17 Ribozyme Pharmaceuticals, Inc. Chemical linkage of ribozyme protions
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
DE69739357D1 (de) * 1996-06-04 2009-05-28 Univ Utah Res Found Überwachung der hybridisierung während pcr
US5780233A (en) * 1996-06-06 1998-07-14 Wisconsin Alumni Research Foundation Artificial mismatch hybridization
US6361940B1 (en) * 1996-09-24 2002-03-26 Qiagen Genomics, Inc. Compositions and methods for enhancing hybridization and priming specificity
CA2218439A1 (en) * 1996-12-21 1998-06-21 Henrik Orum Method of identifying a nucleic acid using triple helix formation of adjacently annealed probes
US6057156A (en) * 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US6025179A (en) * 1998-08-31 2000-02-15 New England Biolabs, Inc. Method for cloning and producing the SnaBI restriction endonuclease and purification of the recombinant SnaBI restriction endonuclease
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000028090A2 (en) * 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US6133031A (en) * 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
US6379932B1 (en) * 2000-07-17 2002-04-30 Incyte Genomics, Inc. Single primer PCR amplification of RNA

Also Published As

Publication number Publication date
EP1173614A1 (en) 2002-01-23
WO2000061810A1 (en) 2000-10-19
KR20020013519A (ko) 2002-02-20
AU777499B2 (en) 2004-10-21
EP1173614A4 (en) 2003-10-29
AU4211900A (en) 2000-11-14
US20030045488A1 (en) 2003-03-06
JP2002541825A (ja) 2002-12-10
CA2365984A1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
IL145586A0 (en) Antisense oligonucleotides comprising universal and/or degenerate bases
IL143379A0 (en) ANTISENSE OLIGONUCLEOTIDE AGAINST HUMAN AChE AND USES THEREOF
GB9800795D0 (en) Prevention of multiple use of limited use devices
PL355101A1 (en) Use of h1
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
HK1049682B (zh) 內切-β-N-乙酰葡糖胺糖苷酶基因
EP1001087A4 (en) SYSTEM FOR DETECTING THE FORM OF A SURFACE COATING AND SURFACE COATING
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
HUP0300560A3 (en) Formulation having mobilising activity
GB9906758D0 (en) Use of locally applied dna fragments
PL337998A1 (en) Temperature-sensitive dtsr gene
AU8371001A (en) Degenerate oligonucleotide gene shuffling
GB2326116B (en) Treatment of chocolate
EP1241256A4 (en) NEW GENE AND USE
GB9807586D0 (en) Enzymes and their use
PL350963A1 (en) Use of arylalkanoylpyridazines
IL126919A0 (en) Antisense oligomer
GB9929581D0 (en) Comjpositions and their use
IL146727A0 (en) Spliceosome protein and its use
EP1210111A4 (en) DNA OF GAMMA HERPESVIRUS AND METHODS OF USE THEREOF
GB9908171D0 (en) Gene and use thereof
HK1050026A1 (zh) 編碼β-微管蛋白的DNA及其應用
GB9929074D0 (en) Releasable retaining devices
IL145409A0 (en) Maize ku80 homolog and uses thereof
GB9801617D0 (en) Oligonucleotides and their uses